Wissam Khalife, MD
Advanced Heart Failure and Transplant Cardiology · Galveston, TXNPI 1477741122
Payments from drug & device makers
Across 586 payments — averaging $1062.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$175K
- Bayer$133K
- Boehringer Ingelheim International GmbH$112K
- Amgen$99K
- Boehringer Ingelheim Pharma GmbH & Co.kg$52K
- Eli Lilly$38K
- plus $14K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $174,636 |
| Bayer | 45 | $133,195 |
| Boehringer Ingelheim International GmbH | 204 | $111,915 |
| Amgen | 29 | $98,609 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 18 | $52,354 |
| Eli Lilly | 13 | $38,135 |
| Abbott | 107 | $6,279 |
| Abiomed | 12 | $1,623 |
| Boston Scientific | 53 | $1,484 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $898 |
| Impulse Dynamics (USA) Inc. | 9 | $765 |
| Biotronik Inc. | 10 | $618 |
| Pfizer | 16 | $442 |
| Nuwellis, Inc. | 3 | $410 |
| Johnson & Johnson | 15 | $338 |
| Medtronic(2 entities) | 3 | $229 |
| E.r. Squibb & Sons, L.L.C. | 5 | $160 |
| Kestra Medical Technology Services, Inc. | 1 | $145 |
| ZOLL Circulation Inc | 1 | $129 |
| Sanofi-aventis U.S. LLC | 2 | $128 |
| Livanova USA, Inc. | 1 | $106 |
| Lexicon Pharmaceuticals, Inc. | 1 | $95 |
| Biosense Webster, Inc. | 1 | $89 |
| Boehringer Ingelheim | 1 | $87 |
| Alnylam Pharmaceuticals Inc. | 2 | $32 |
| Venclose Inc. | 1 | $6 |
How this compares
$622,906 in reported general payments places this provider in the 90th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in Galveston
- Khaled ChatilaGalveston$7K
- Shareef MansourGalveston$4K
- Robert GottliebDallas$14.1M
- Martin BerkDallas$1.9M
- Kunjan BhattAustin$1.6M
- Ajith NairHouston$1.3M
- Shelley HallDallas$1.3M
- Aasim AfzalPlano$1.2M
- Albert HicksTemple$656K
- Allen AndersonSan Antonio$615K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.